Prostate cancer is a leading health concern for men worldwide and can present as slow-growing tumors or as rapidly progressing, life-threatening disease. Sadly, African-American men face higher rates of aggressive prostate cancer and a greater risk of dying from the disease compared to other groups. While treatments such as hormone therapy and chemotherapy can initially help many patients, these approaches often fail over time—especially in African-American men whose tumors have distinctive molecular features. To address these challenges, our project focuses on three key steps aimed at uncovering new drug targets and advancing precision treatments. First, we will collect and organize information on existing drugs, clinical trial results, and genetic and protein, gene expression data from both African-American and European-American populations. Second, we will apply cutting-edge artificial intelligence (AI) models—specifically, large language models (LLMs)—to analyze the collected data. These AI models will predict which drug targets might be most effective for men from diverse racial backgrounds. Third, we will develop specialized AI models for African-American men, European-American men, and one combined model covering everyone, allowing us to see which treatments are likely to work best for each group or broadly for all. We will test our highest-priority targets using the lab data to confirm that they can be targeted effectively by new or existing drugs. Finally, in partnership with MD Anderson’s Therapeutics Discovery Division, we will rapidly move the most promising targets into the early stages of drug development (through separate funding). By emphasizing the specific needs of African-American men—while still benefiting all men with prostate cancer—our work aims to offer more personalized and potent treatment options. We believe this approach will reduce longstanding health disparities in prostate cancer care and serve as a blueprint for improving outcomes in other cancers as well.